Scan to Download
One power score. Smarter investment decisions
Jasper Therapeutics Inc
JSPR2.500USD
-0.090-3.47%
收盤 09/19, 16:00（美東）報價延遲15分鐘
USD0.000盤後交易 (美東)
40.55M總市值
虧損本益比TTM
單季報
單季報+年報
單季報
年報
YOY
隱藏空白列
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
營業費用
69.30%27.08M
44.65%21.80M
42.65%25.29M
2.72%19.89M
-10.29%15.99M
8.07%15.07M
28.94%17.73M
52.36%19.36M
49.02%17.83M
9.15%13.95M
13.78%13.75M
26.08%12.71M
42.11%11.96M
104.32%12.78M
102.79%12.08M
67.76%10.08M
--8.42M
--6.25M
--5.96M
--6.01M
研發費用
87.64%21.20M
56.89%16.16M
42.91%19.77M
-2.65%14.46M
-15.05%11.30M
5.03%10.30M
49.05%13.84M
64.58%14.85M
63.45%13.30M
19.75%9.80M
7.22%9.28M
25.51%9.02M
57.78%8.13M
85.25%8.19M
86.29%8.66M
59.03%7.19M
--5.16M
--4.42M
--4.65M
--4.52M
折舊攤銷及損耗
0.00%300.00K
0.00%300.00K
6.01%300.00K
96.01%541.00K
9.09%300.00K
9.49%300.00K
-5.67%283.00K
-8.00%276.00K
26.15%275.00K
26.85%274.00K
38.25%300.00K
127.27%300.00K
651.72%218.00K
881.82%216.00K
--217.00K
--132.00K
--29.00K
--22.00K
--0.00
--0.00
營業利潤
-69.30%-27.08M
-44.65%-21.80M
-42.65%-25.29M
-2.72%-19.89M
10.29%-15.99M
-8.07%-15.07M
-28.94%-17.73M
-52.36%-19.36M
-49.02%-17.83M
-9.15%-13.95M
-13.78%-13.75M
-26.08%-12.71M
-42.11%-11.96M
-104.32%-12.78M
-102.79%-12.08M
-67.76%-10.08M
---8.42M
---6.25M
---5.96M
---6.01M
淨非營業利息收入（費用）
利息收入
-69.86%437.00K
-54.98%624.00K
-23.99%938.00K
-10.40%1.28M
0.97%1.45M
26.46%1.39M
--1.23M
--1.43M
--1.44M
--1.10M
----
----
----
----
----
----
----
----
----
----
特殊收入（費用）
----
----
----
-94.01%20.00K
----
98.51%-20.00K
-88.09%28.00K
-42.11%334.00K
-71.43%420.00K
-112.58%-1.34M
-92.42%235.00K
-91.36%577.00K
--1.47M
404.00%10.64M
177.31%3.10M
241.86%6.68M
--0.00
---3.50M
---4.01M
---4.71M
其他非經營性收入（費用）
-110.00%-84.00K
-186.36%-63.00K
122.03%26.00K
-201.96%-52.00K
63.30%-40.00K
68.57%-22.00K
-139.20%-118.00K
-80.97%51.00K
-222.47%-109.00K
2.78%-70.00K
476.25%301.00K
--268.00K
9000.00%89.00K
-7300.00%-72.00K
---80.00K
----
---1.00K
--1.00K
----
----
稅前利潤
-83.25%-26.72M
-54.73%-21.24M
-46.68%-24.32M
-6.23%-18.64M
9.31%-14.58M
3.73%-13.73M
-25.51%-16.58M
-47.89%-17.54M
-54.56%-16.08M
-546.13%-14.26M
-45.87%-13.21M
-247.68%-11.86M
-23.65%-10.40M
77.37%-2.21M
9.31%-9.06M
68.48%-3.41M
---8.41M
---9.75M
---9.99M
---10.82M
除稅後利潤
-83.25%-26.72M
-54.73%-21.24M
-46.68%-24.32M
-6.23%-18.64M
9.31%-14.58M
3.73%-13.73M
-25.51%-16.58M
-47.89%-17.54M
-54.56%-16.08M
-546.13%-14.26M
-45.87%-13.21M
-247.68%-11.86M
-23.65%-10.40M
77.37%-2.21M
9.31%-9.06M
68.48%-3.41M
---8.41M
---9.75M
---9.99M
---10.82M
持續經營利潤
-83.25%-26.72M
-54.73%-21.24M
-46.68%-24.32M
-6.23%-18.64M
9.31%-14.58M
3.73%-13.73M
-25.51%-16.58M
-47.89%-17.54M
-54.56%-16.08M
-546.13%-14.26M
-45.87%-13.21M
-247.68%-11.86M
-23.65%-10.40M
77.37%-2.21M
9.31%-9.06M
68.48%-3.41M
---8.41M
---9.75M
---9.99M
---10.82M
歸属于母公司的淨利潤
-83.25%-26.72M
-54.73%-21.24M
-46.68%-24.32M
-6.23%-18.64M
9.31%-14.58M
3.73%-13.73M
-25.51%-16.58M
-47.89%-17.54M
-54.56%-16.08M
-546.13%-14.26M
-45.87%-13.21M
-247.68%-11.86M
-23.65%-10.40M
77.37%-2.21M
9.31%-9.06M
68.48%-3.41M
---8.41M
---9.75M
---9.99M
---10.82M
歸屬普通股東的淨利潤
-83.25%-26.72M
-54.73%-21.24M
-46.68%-24.32M
-6.23%-18.64M
9.31%-14.58M
3.73%-13.73M
-25.51%-16.58M
-47.89%-17.54M
-54.56%-16.08M
-546.13%-14.26M
-45.87%-13.21M
-247.68%-11.86M
-23.65%-10.40M
77.37%-2.21M
9.31%-9.06M
68.48%-3.41M
---8.41M
---9.75M
---9.99M
---10.82M
基本每股收益
-79.09%-1.74
-37.35%-1.41
-7.98%-1.62
22.30%-1.24
33.91%-0.97
36.35%-1.03
58.37%-1.50
50.71%-1.60
48.49%-1.47
-166.12%-1.62
-51.10%-3.60
-259.56%-3.24
-28.47%-2.86
76.44%-0.61
9.68%-2.39
68.48%-0.90
---2.23
---2.58
---2.64
---2.86
稀釋每股收益
-79.09%-1.74
-37.35%-1.41
-7.98%-1.62
22.30%-1.24
33.91%-0.97
36.35%-1.03
58.37%-1.50
50.71%-1.60
48.49%-1.47
-166.12%-1.62
-51.10%-3.60
-259.56%-3.24
-28.47%-2.86
76.44%-0.61
9.68%-2.39
68.48%-0.90
---2.23
---2.58
---2.64
---2.86
每股派息
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
貨幣單位
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
審計意見
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
